TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis
Key facts
- Who runs it
- University of Regensburg
- Where
- Austin and Champaign, United StatesSee the 2 sitesAlso in 4 other countries, 5 sites
- Trial code
- Status
- Completed
- People taking part
- 560 people enrolled
- Started
- 1 Aug 2024
- Ended
- 30 Nov 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Acoustic paradigms
- Record updated
- 24 March 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- (1) for tinnitus cases: a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
- (2) for controls: never experienced tinnitus
- (3) age 18 -70
- (4) ability to understand and consent to the research
- (5) ability to participate (hearing ability)
- (6) MoCa Test ≥ 26
- (7) hyperacusis questionnaire score < 27
Who cannot take part
- (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start
- (9) change in anti-depressants/drugs ≤ 2 weeks
- (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing
- (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis)
- (4) Meniere's disease or similar syndromes
- (6) serious internal, neurological or psychiatric conditions
- (7) epilepsy or other CNS disorders (brain tumor, encephalitis)
- (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint
- (5) vestibular migraine
- (10) missing written informed consent
- (11) severe hearing loss - inability to communicate properly in the course of the study
- (12) one deaf ear
Where in United States
Also in 4 other countries, 5 sites
- University of TexasAustin, United States
- University of IllinoisChampaign, United States
About the trial
What the trial wants to find out
Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a personalized approach to the diagnosis and treatment of tinnitus. The overarching goal of this study is to incorporate advanced technologies to provide an objective, data-driven, personalized approach to the diagnosis of chronic tinnitus. This should lead to a clinically applicable tool that can be widely and easily used.
The 2 groups in the trial
- Tinnitus cases/patients
Subjects that have a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
Treatment: Acoustic paradigms
- Control group
Subjects that never experienced tinnitus (excluding short-term tinnitus, i.e. not tinnitus that persists over a longer period of time)
Treatment: Acoustic paradigms
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identification and Validation of a Biomarker for Tinnitus: an Objective Data-driven Personalized Approach to Diagnosis of Chronic Tinnitus - The Tinnitus Detection (TIDE) Project
- Publications
- Record updated
- 24 March 2026